Search
forResearch 10 of 119
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- The PDGF/PDGFR pathway as a drug target
- Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
- Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Nilotinib-induced generalized keratosis pilaris: Report of a rare case
- Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →